SCHEMBL2250463

SCHEMBL2250463

CC#CCN(C(=O)Nc1cc(C(N)=O)c(F)cc1F)C1CCN(Cc2ccc(Oc3ccc(CS(C)(=O)=O)cc3)nc2C)CC1

nearest known ligand 0.35

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CCR5 P51681 6/20 0.35
KCNH2 Q12809 3/20 0.35
THRB P10828 2/20 0.33
CDK1 P06493 1/20 0.33
CDK2 P24941 1/20 0.33
CDK8 P49336 1/20 0.33
CCR4 P51679 2/20 0.32
TP53 P04637 2/20 0.32
LMNA P02545 2/20 0.32
UBE2M P61081 2/20 0.31
DCUN1D1 Q96GG9 2/20 0.31
DRD2 P14416 1/20 0.31
ADRA1A P35348 1/20 0.31
GPR119 Q8TDV5 1/20 0.31
KDR P35968 3/20 0.31
MET P08581 2/20 0.31
GALR3 O60755 1/20 0.31
RAB9A P51151 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2251803 0.93 DRD2 (0.33) CCR5KCNH2THRBCDK1CDK2
SCHEMBL2252142 0.93 CCR5 (0.35) CCR5KCNH2THRBCDK1CDK2
SCHEMBL2253313 0.92 CCR5 (0.36) CCR5KCNH2THRBCDK1CDK2
SCHEMBL2250434 0.91 CDK2 (0.36) CCR5KCNH2THRBCDK1CDK2
SCHEMBL2256690 0.91 CCR5 (0.36) CCR5KCNH2THRBCDK1CDK2
SCHEMBL2254711 0.89 CCR5 (0.36) CCR5KCNH2THRBCDK1CDK2
SCHEMBL2256106 0.88 CCR5 (0.36) CCR5KCNH2CDK1CDK2CDK8
SCHEMBL2251160 0.86 CCR5 (0.37) CCR5KCNH2THRBCCR4LMNA
SCHEMBL30227275 0.86 CCR5 (0.37) CCR5KCNH2THRBCCR4LMNA
SCHEMBL2255297 0.85 DRD2 (0.33) THRBCDK1CDK2CDK8UBE2M

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8003642-B2 Nitrogenated heterocyclic derivative, and pharmaceutical agent comprising the derivative as active ingredient ONO PHARMACEUTICAL CO., LTD. (JP) 2011-08-23 US claimed
US-20090131403-A1 NITROGENATED HETEROCYCLIC DERIVATIVE , AND PHARMACEUTICAL AGENT COMPRISING THE DERIVATIVE AS ACTIVE INGREDIENT ONO PHARMACEUTICAL CO., LTD. (JP) 2009-05-21 US disclosed
EP-1995246-A1 NITROGENATED HETEROCYCLIC DERIVATIVE, AND PHARMACEUTICAL AGENT COMPRISING THE DERIVATIVE AS ACTIVE INGREDIENT ONO PHARMACEUTICAL CO., LTD. (JP) 2008-11-26 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090131403-A1 NITROGENATED HETEROCYCLIC DERIVATIVE , AND PHARMACEUTICAL AGENT COMPRISING THE DERIVATIVE AS ACTIVE INGREDIENT CXCR3, CCR5, HLA-DRB1 CCR5 2/4885KCNH2 4115/4885THRB 3300/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.